[Evaluation of in vitro antibacterial activity of fosmidomycin and its derivatives]

Insights

Fosmidomycin, an antibiotic targeting the methyl-erythritol phosphate pathway (MEP), shows varied efficacy against bacteria. Combinations with membrane-disrupting agents enhance its activity against resistant strains.

Area of Science:

  • Microbiology
  • Drug Discovery
  • Biochemistry

Background:

  • Pathogenic microorganisms utilize the methyl-erythritol phosphate pathway (MEP) for isoprenoid synthesis, distinct from mammals.
  • MEP enzymes are potential targets for novel antibiotic development.
  • Polyprenyl compounds are crucial macromolecules in microbial cell metabolism.

Purpose of the Study:

  • To evaluate the antibacterial activity of fosmidomycin, an inhibitor of 1-deoxy-D-xylulose-5-phosphate reductoisomerase (DXR).
  • To investigate the mechanisms of fosmidomycin resistance in various bacterial species.
  • To explore strategies for enhancing fosmidomycin's efficacy against resistant pathogens.

Main Methods:

  • In vitro susceptibility testing of fosmidomycin against diverse bacterial strains.
  • Determination of Minimum Inhibitory Concentrations (MICs) using serial dilution methods.
  • Assessment of fosmidomycin derivatives and combination therapies to overcome resistance.

Main Results:

  • Bacterial strains exhibited variable susceptibility to fosmidomycin, with MICs ranging from 1 to 512 mcg/ml.
  • Vaccinal strains of B. anthracis and P. aeruginosa were susceptible, while Listeria, Yersinia, and Burkholderia showed intermediate resistance.
  • Enteric bacteria, Mycobacterium, Corynebacterium, Campylobacterium, and tularemia strains were resistant.
  • Modifying fosmidomycin's hydrophoby did not improve efficacy; combination therapy with polymyxin B, chlorhexidine, or cetrimide significantly lowered MICs for resistant strains.

Conclusions:

  • Bacterial resistance to fosmidomycin may stem from impaired drug delivery to the DXR target.
  • Enhancing fosmidomycin's cellular penetration is key to overcoming resistance.
  • Combination therapies with membrane-active agents represent a promising strategy to potentiate fosmidomycin's antibacterial effects.